AU2019392680B2 - Neuroactive steroids and their methods of use - Google Patents

Neuroactive steroids and their methods of use Download PDF

Info

Publication number
AU2019392680B2
AU2019392680B2 AU2019392680A AU2019392680A AU2019392680B2 AU 2019392680 B2 AU2019392680 B2 AU 2019392680B2 AU 2019392680 A AU2019392680 A AU 2019392680A AU 2019392680 A AU2019392680 A AU 2019392680A AU 2019392680 B2 AU2019392680 B2 AU 2019392680B2
Authority
AU
Australia
Prior art keywords
methods
neuroactive steroids
neuroactive
steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019392680A
Other languages
English (en)
Other versions
AU2019392680A1 (en
Inventor
Maria Jesus Blanco-Pillado
Marshall Lee Morningstar
Francesco G. Salituro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of AU2019392680A1 publication Critical patent/AU2019392680A1/en
Priority to AU2025203487A priority Critical patent/AU2025203487A1/en
Priority to AU2025203485A priority patent/AU2025203485A1/en
Application granted granted Critical
Publication of AU2019392680B2 publication Critical patent/AU2019392680B2/en
Assigned to Sage Therapeutics, LLC reassignment Sage Therapeutics, LLC Request to Amend Deed and Register Assignors: SAGE THERAPEUTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019392680A 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use Active AU2019392680B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2025203487A AU2025203487A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use
AU2025203485A AU2025203485A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775470P 2018-12-05 2018-12-05
US62/775,470 2018-12-05
PCT/US2019/064692 WO2020118060A1 (en) 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2025203487A Division AU2025203487A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use
AU2025203485A Division AU2025203485A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use

Publications (2)

Publication Number Publication Date
AU2019392680A1 AU2019392680A1 (en) 2021-06-10
AU2019392680B2 true AU2019392680B2 (en) 2025-07-10

Family

ID=69006056

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019392680A Active AU2019392680B2 (en) 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use
AU2025203487A Pending AU2025203487A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use
AU2025203485A Pending AU2025203485A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2025203487A Pending AU2025203487A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use
AU2025203485A Pending AU2025203485A1 (en) 2018-12-05 2025-05-14 Neuroactive steroids and their methods of use

Country Status (14)

Country Link
US (8) US20230322846A9 (https=)
EP (1) EP3902818A1 (https=)
JP (3) JP7539378B2 (https=)
KR (2) KR20250174100A (https=)
CN (1) CN113383004A (https=)
AR (1) AR117264A1 (https=)
AU (3) AU2019392680B2 (https=)
BR (1) BR112021010996A2 (https=)
CA (1) CA3120872A1 (https=)
IL (3) IL283629B2 (https=)
MA (1) MA54594A (https=)
MX (4) MX2021006618A (https=)
TW (2) TW202521127A (https=)
WO (1) WO2020118060A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
EP3728284B1 (en) * 2017-12-22 2024-08-21 Sage Therapeutics, Inc. 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
CN113195512A (zh) * 2018-12-21 2021-07-30 萨奇治疗股份有限公司 3.α.-羟基-17.β.-酰胺神经活性类固醇及其组合物
CR20240234A (es) * 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス， エルエルシー Ｃｎｓ障害を治療するための組成物及び方法
US20230257415A1 (en) * 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
TW202143976A (zh) * 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
CN112679571A (zh) * 2020-12-24 2021-04-20 广西壮族自治区中国科学院广西植物研究所 一种罗汉果醇衍生物单体、其制备方法及应用
JP2024532273A (ja) * 2021-08-25 2024-09-05 セージ セラピューティクス， インコーポレイテッド ポジティブｎｍｄａモジュレート化合物及びその使用方法
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
KR20250162825A (ko) 2023-03-14 2025-11-19 쿠리아 스페인, 에스.에이.유. 3알파-하이드록시-3베타-알킬 스테로이드의 제조를 위한 방법 및 중간체
WO2024197317A2 (en) * 2023-03-23 2024-09-26 Emory University Neurosteroids and prodrugs thereof
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) * 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
WO1996016076A1 (en) * 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2017049044A1 (en) * 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
FR2967914A1 (fr) 2010-11-29 2012-06-01 Centre Nat Rech Scient Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2017187343A2 (en) 2016-04-29 2017-11-02 Thome Kreutz Fernando Nanoemulsions and methods for cancer therapy
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
US20200384003A1 (en) 2017-12-29 2020-12-10 Shanghai Lanmu Chemicals Co., Ltd. Triterpenoid-containing pharmaceutical composition and use thereof
CN114656514B (zh) 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
EP3852764A4 (en) 2018-09-19 2022-06-15 ModernaTX, Inc. STEROL ANALOGUES AND USES THEREOF
CN113195512A (zh) 2018-12-21 2021-07-30 萨奇治疗股份有限公司 3.α.-羟基-17.β.-酰胺神经活性类固醇及其组合物
WO2020210117A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210116A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
CN114144185A (zh) 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
US20230257415A1 (en) 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
US20220396597A1 (en) 2019-10-25 2022-12-15 Washington University Nmdar inhibiting agents and gabaar potentiating agents and uses thereof
IL299176A (en) 2020-06-24 2023-02-01 Sage Therapeutics Inc 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) * 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
WO1996016076A1 (en) * 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2017049044A1 (en) * 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders

Also Published As

Publication number Publication date
IL312611B1 (en) 2025-05-01
JP2022510683A (ja) 2022-01-27
JP2025134803A (ja) 2025-09-17
US20230046825A1 (en) 2023-02-16
IL283629B1 (en) 2025-11-01
MX2024004790A (es) 2024-05-09
IL283629B2 (en) 2026-03-01
US20230322849A1 (en) 2023-10-12
AU2025203485A1 (en) 2025-05-29
US11999765B2 (en) 2024-06-04
MX2024004789A (es) 2024-05-09
JP7720948B2 (ja) 2025-08-08
US20230322847A1 (en) 2023-10-12
CN113383004A (zh) 2021-09-10
AU2019392680A1 (en) 2021-06-10
US12264177B2 (en) 2025-04-01
MA54594A (fr) 2022-04-06
US20250154194A1 (en) 2025-05-15
TW202521127A (zh) 2025-06-01
AR117264A1 (es) 2021-07-21
US11912738B2 (en) 2024-02-27
MX2021006618A (es) 2021-09-23
AU2025203487A1 (en) 2025-05-29
MX2024004788A (es) 2024-05-09
IL312610B1 (en) 2026-01-01
EP3902818A1 (en) 2021-11-03
US20230322848A1 (en) 2023-10-12
TWI874337B (zh) 2025-03-01
IL312610A (en) 2024-07-01
IL283629A (en) 2021-07-29
WO2020118060A1 (en) 2020-06-11
TW202039528A (zh) 2020-11-01
US20240343756A1 (en) 2024-10-17
US12410210B2 (en) 2025-09-09
JP7539378B2 (ja) 2024-08-23
IL312611B2 (en) 2025-09-01
KR20250174100A (ko) 2025-12-11
CA3120872A1 (en) 2020-06-11
JP2024105504A (ja) 2024-08-06
US11970514B2 (en) 2024-04-30
KR20210112318A (ko) 2021-09-14
US20230322846A9 (en) 2023-10-12
KR102892974B1 (ko) 2025-11-28
BR112021010996A2 (pt) 2021-08-31
US20240336648A1 (en) 2024-10-10
US20240309042A1 (en) 2024-09-19
TW202521129A (zh) 2025-06-01
IL312611A (en) 2024-07-01
US12252509B2 (en) 2025-03-18

Similar Documents

Publication Publication Date Title
AU2019392680B2 (en) Neuroactive steroids and their methods of use
IL273099A (en) Neuroactive steroids and methods of using them
CA3279953A1 (en) C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP3625253A4 (en) ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
EP3886853A4 (en) DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF
EP3642231A4 (en) ANTI-VISTA ANTIBODIES AND METHODS OF USE
EP3911331A4 (en) TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
ZA202100093B (en) Neuroactive steroids and methods of preparation
EP3755407A4 (en) INHALER AND METHOD OF USE THEREOF
TWI924370B (zh) 神經活性類固醇及其使用方法
HK40063679A (en) Neuroactive steroids and their methods of use
HK40033089A (en) Neuroactive steroids and their methods of use
HK40052007A (en) Neuroactive steroids and methods of preparation
EP3595776A4 (en) FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE
HK40055592A (en) Catabodies and methods of use thereof
HK40053358A (en) Anellosomes and methods of use
HK40043593A (en) Imidazodiazepinediones and methods of use thereof
HK40088110A (en) Neuroactive steroids and their methods of use
HK40051102A (zh) 秋水仙碱衍生物的方法和用途
HK40045754A (en) B7-h7-binding agents and methods of use thereof
HK40036467A (en) Fulvestrant formulations and methods of their use
HK40054782A (en) Anti-il-36 antibodies and methods of use thereof
HK40043133A (en) Inhaler and methods of use thereof
HK40050351A (en) Hepato-biliary-pancreatic tissues and methods of making same

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BLANCO-PILLADO, MARIA JESUS; SALITURO, FRANCESCO G. AND MORNINGSTAR, MARSHALL LEE

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SAGE THERAPEUTICS, LLC

Free format text: FORMER NAME(S): SAGE THERAPEUTICS, INC.